Dendreon Will Likely Require Refinancing Before Re-Submitting Provenge BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company believes it has the necessary cash to extend through timing of interim results of IMPACT study evaluating the cancer vaccine in 2008.